molecules of the month

“compound 5i”

oral, brain-penetrant O-GlcNAcase (OGA) inh.

structurally distinct in vivo tool

from virtual screen of 100k cmpd, testing 2681

J. Med. Chem., Jan. 6, 2021

Takeda Pharmaceutical, Fujisawa, JP

Chemical structure of compound-5i Takeda O-GlcNAcase (OGA) inhibitor
1 min read

The Takeda O-GlcNAcase (OGA) inhibitor, “compound 5i,” binds to the same site as prior sugar-based OGA inhibitors, but has surprisingly different chemical properties and a unique binding mode. The Takeda team realized that polar, sugar-based OGA inhibitors would be challenging to get into the brain where they would be needed for neurodegenerative diseases, and so used an elegant virtual-screening and structure-based approach to make the leap to the distinct, CNS-friendly starting point for compound 5i. The less basic pyrimidine N(1) nitrogen (pKa ~ 4.9) surprisingly appears to be protonated in the binding site, making a bidentate interaction with a carboxylate, likely helped by the presence of a second Asp residue. The article is a great case-study for identifying distinct new…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: